Skip to main content
Clinical Trials/DRKS00013497
DRKS00013497
Completed
Not Applicable

Study on the incidence of genetic polymorphism in patients with major depression who are treated unsatisfactory with antidepressants - GENADET

STADAPHARM GmbH0 sites252 target enrollmentDecember 8, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Genetic polymorphism of drug metabolizing
Sponsor
STADAPHARM GmbH
Enrollment
252
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 8, 2017
End Date
May 15, 2020
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Outpatients with a diagnosis of major depression
  • First drug treatment with one of the following active substances since max. two weeks:
  • \-Citalopram
  • \-Escitalopram
  • \-Amitriptyline
  • \-Venlafaxine
  • Age \=18 years
  • Capacity to consent

Exclusion Criteria

  • Comedication with influence on the activity of the enzymes CYP2C19 and CYP2D6
  • Intake of St. John's wort preparations
  • Consumption of grapefruit and / or products
  • Consumption of tryptophan\-containing dietary supplements
  • Change of medication within the last 3 months
  • Hepatic insufficiency (from Child\-Pugh\-stage A)
  • Renal insufficiency stage 3 (glomerular filtration rate \<60 ml / min / 1\.73 m²)
  • Addiction
  • Schizophrenia
  • Bipolar affective disorder

Outcomes

Primary Outcomes

Not specified

Similar Trials